Table 2.
BRAF inhibitors in metastatic colorectal cancer.
| Variation | Reference | Patients, n (Type of Study) |
Treatment | ORR (%) | PFS (Months) | OS (Months) |
|---|---|---|---|---|---|---|
| BRAF inhibitor monotherapy | Kopetz [66] | 21 Phase II |
vemurafenib | 5 | 2.1 | 7.7 |
| Hyman [67] | 10 Phase II “basket” |
vemurafenib | 0 | 4.5 | 9.3 | |
| BRAF inhibitor + MEK inhibitor | Corcoran [68] | 43 Phase I/II |
dabrafenib + trametinib | 12 | 3.5 | - |
| BRAF inhibitor + EGFR inhibitor | Kopetz BEACON [72] |
220 Phase III |
encorafenib + cetuximab | 20 | 4.2 | 8.4 |
| Triplet therapy | Kopetz BEACON [72] |
224 Phase III |
encorafenib + cetuximab + binimetinib | 26 | 4.3 | 9.0 |
ORR, objective response rate; PFS, progression-free survival; OS, overall survival.